NewsRoom Articles - Page 52 of 219

FridayFeb 09, 2024 11:00 am

The Right to Health During Humanitarian Crises Should Include Noncommunicable Diseases

Estimates from the United Nations show that about 363 million individuals worldwide are affected by humanitarian crises driven by the climate crisis, increase conflict and fragility, and broadening inequality. In 2022, more than 108 million individuals were forced to flee their homes due to conflict. While humanitarian crises such as those currently occurring in Gaza, Sudan, Libya, Somalia and Ukraine may vary in scale and nature, they all share infrastructure demolition, displacement of the masses, and the disruption of services and supply chains. Healthcare facilities are also heavily impacted in times of conflict, particularly because they are directly targeted. Access…

WednesdayFeb 07, 2024 10:15 am

Patients with Swelling Disorder See New Gene Therapy as Godsend

A new gene therapy is transforming the lives of patients with a debilitating hereditary condition that causes painful and even fatal levels of swelling. The therapy led to significantly promising results in its first trial involving humans, with patients involved in the study reporting “dramatic improvements” in their symptoms that allowed them to stop taking long-term medication and resume their regular day-to-day activities. Hereditary angioedema is a rare condition that arises from a genetic mutation and causes leaky blood vessels in patients. This leads to random bouts of swelling that can affect the hand, feet, throat, bowels, mouth and lips…

WednesdayFeb 07, 2024 9:00 am

Longeveron Inc.’s (NASDAQ: LGVN) Long-Term Follow-Up Data from Its ELPIS I Clinical Trial Presented at the 2023 Annual Scientific Sessions of the American Heart Association

A poster about Longeveron’s long-term follow-up data from its ELPIS I clinical trial was presented at the 2023 Scientific Sessions of the American Heart Association in November 2023 The poster showed that 100% of the 10 patients enrolled in the study survived and remained heart transplant-free for up to 5 years of age after receiving Lomecel-B(TM) during their Stage II surgery The data supports Longeveron’s ongoing ELPIS II study, which has exceeded its 50% enrollment threshold The company believes the long-term follow-up data underscore the potential for Lomecel-B(TM) as a much-needed therapeutic innovation for HLHS patients Historical results from outside…

TuesdayFeb 06, 2024 11:45 am

How AI Could Revolutionize Personalization in e-Commerce

According to a 2021 study by McKinsey & Company, 71% of customers expect companies to deliver personalized experiences while 78% choose to pay higher prices for personalized services or custom services. The study revealed that companies with great personalization earn roughly 40% more revenue from personalization-related activities compared to companies with average personalization. The research also found that 75% of customers recently tried a new shopping behavior, indicating that it is getting increasingly hard for brands to gain and retain customer loyalty. Personalization has become very important to customers who, on average, expect some degree of personalization in their interactions…

TuesdayFeb 06, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Reports ‘Unprecedented,’ Statistically Significant Long-Term Clinical Improvements for VISIONARY-MS Trial Participants with Stable Relapsing-Remitting MS

Clene recently reported new results from the open-label, long-term extension (“LTE”) of the VISIONARY-MS trial, involving participants with stable relapsing Multiple Sclerosis (“MS”) through week 144 (over 2.75 years) after the initial randomization Results from the 48-week double-blind period showed statistically significant improvements in vision (primary endpoint), as well as a combined improvement in cognition, walking speed, upper extremity function, and vision (secondary endpoint) with CNM-Au8 treatment, with further significant improvements in both vision and cognition extending throughout the 96-week LTE One of the trial’s key clinical advisors hailed the results as robust and consistent, describing the observed long-term clinical…

MondayFeb 05, 2024 12:00 pm

Astiva Health Differentiating Itself in Medicare Market, Working to Provide ‘Robust, Stable’ Offerings

CMS forecasts enrollment in Medicare Advantage programs will increase from 31.6 million in 2023 to 33.8 million in 2024 Astiva Health recently expanded into three Southern California counties, resulting in the company reaching the 10,000-member milestone mark Astiva is committed to reshape healthcare delivery, increased access to quality healthcare In a space where a growing number of individuals are qualifying for Medicare, Astiva Health is differentiating itself as a fast-growing Medicare Advantage Prescription Drug (“MAPD”) health plan focused on redefining the standards of personalized and comprehensive healthcare. As an indication of its success in, Astiva company recently reached a key milestone, surpassing the…

MondayFeb 05, 2024 10:45 am

Scientists Start Trialing First Blood Test Against Brain Cancer

Brain tumors, which affects thousands of individuals around the globe, can be diagnosed using various imaging techniques, including magnetic resonance imaging (MRI) and computed tomography (CT) scans. Some tumors cannot be diagnosed using these techniques, however, which makes it hard for them to be detected earlier. In the United Kingdom, brain tumors kill more individuals aged 40 and below than any other cancer. Now, researchers have developed a blood test that may revolutionize the diagnosis of brain cancer. The blood test, called the TriNetra-Glio test, may help diagnose patients with different types of brain cancer earlier, which could eliminate the…

MondayFeb 05, 2024 9:00 am

Astrotech Corp. (NASDAQ: ASTC) Positioning TRACER 1000(TM) as Next-Generation Solution for the Explosive Trace Detector Market

1st Detect, a wholly owned subsidiary of mass spectrometry company Astrotech, is offering its breakthrough TRACER 1000(TM) Explosive Trace Detector (“ETD”) in markets that accept ECAC certification The TRACER 1000(TM) ETD is designed to outperform ETDs currently used at airports, cargo and other secured facilities, as well as at borders Astrotech is working to position its product as the next-generation solution for the ETD market at a time when many of the existing IMS-based ETDs are due for replacement Keenly watching the developments in the field of explosives and narcotics detection at airports is Astrotech (NASDAQ: ASTC), a mass spectrometry…

FridayFeb 02, 2024 12:48 pm

New Study Challenges Perception of Males Being More Susceptible to Autism

A research team led by Manish Kumar Tripathi, a neuroscientist from the Hebrew University of Jerusalem, has published findings challenging the idea that males are more susceptible to autism than females. The team studied the condition in a mouse model and found that both male and female brains have equal chances of developing the condition. Autism is a neurological and developmental disorder that affects how individuals learn, communicate, behave and interact with others. While autism is diagnosable at nearly any age, it is typically classified as a “developmental disorder” because its symptoms usually appear in the first two years of…

ThursdayFeb 01, 2024 2:12 pm

Why Prescription Drugs Can Be Costly

Prescription drugs have had a significant impact on human society. From treating temporary conditions and controlling chronic conditions, prescription drugs have been critical to preserving long-term health and quality of life for millions of people for well over a century. However, prescription drugs tend to be quite expensive in the United States when compared to other countries. A 2023 RAND Corporation study found that brand-name prescription drug prices in the U.S. were 3.44 times higher compared to 32 similar nations. According to a Kaiser Family Foundation Health Tracking Poll, 8 in 10 U.S. adults believe prescription medication prices in the…